Cargando…
Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne muscular dystrophy
BACKGROUND: Adolescents with DMD treated with chronic high dose GC therapy typically have profound pubertal delay. Testosterone, the main circulating androgen in men, promotes virilisation and growth with associated accrual of fat-free muscle mass and bone mineral content. Testosterone therapy is ro...
Autores principales: | Wood, C. L., Cheetham, T. D, Hollingsworth, K. G, Guglieri, M., Ailins-Sahun, Y., Punniyakodi, S., Mayhew, A., Straub, V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482579/ https://www.ncbi.nlm.nih.gov/pubmed/31023296 http://dx.doi.org/10.1186/s12887-019-1503-x |
Ejemplares similares
-
Is ongoing testosterone required after pubertal induction in Duchenne muscular dystrophy?
por: Wood, Claire L, et al.
Publicado: (2023) -
MON-LB050 Preliminary Results from the "Observational Study of Clinical Outcomes for Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy (DMD) (NCT 02571205)"
por: Wood, Claire, et al.
Publicado: (2019) -
Measurement of salivary testosterone in adolescents and young men with Duchenne muscular dystrophy
por: Sahun, Yolanda Alins, et al.
Publicado: (2021) -
The impact of testosterone therapy on quality of life in adolescents with Duchenne muscular dystrophy
por: Wood, CL, et al.
Publicado: (2021) -
Quantifying the burden of caregiving in Duchenne muscular dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2016)